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Abstract
Lead characteristically perturbs processes linked to the calcium messenger system. This study was undertaken to
2q w 2qx w 2qxdetermine the role of PKC in the Pb induced rise of Ca . Ca was measured using the divalent cation indicator,i i
 . X X  . 191,2-bis 2-amino-5-fluorophenoxy ethane N, N,N ,N -tetraacetic acid 5F-BAPTA and F-NMR in the osteoblast cell line,
2q w 2qxROS 17r2.8. Treatment of cells with Pb at 1 and 5 mM produced a rise in Ca from a basal level of 125 nM to 170i
 .  .nM and 230 nM, respectively, while treatment with phorbol 12-myristate 13-acetate PMA 10 mM , an activator of PKC,
w 2qxproduced a rise in Ca to 210 nM. Pretreatment with calphostin C, a potent and highly selective inhibitor of PKCi
w 2qx w 2qx 2qactivation failed to produce a change in basal Ca and prevented any rise in Ca in response to Pb . To determinei i
whether Pb2q acts directly on PKC, we measured the Pb2q-dependent activation of phosphatidylserinerdiolein-dependent
incorporation of 32 P from ATP into histone and endogenous TCA precipitable proteins in the 100 000=g supernatant from
2q 2q w 2qxhomogenized ROS 17r2.8 cells. The free concentrations of Pb and Ca were set using 5F-BAPTA; and Ca and
w 2qx 19 2qPb in the PKC reaction mixtures were confirmed by F-NMR. We found that Pb activates PKC in the range of
10y11–10y7 M, with an activation constant of 1.1=10y10 M, whereas Ca2q activates PKC in the range from 10y8 to
10y3 M, with an activation constant of 3.6=10y7 M. These data suggest that Pb2q activates PKC in ROS 17r2.8 cells
2q w 2qx 2qand that Pb activation of PKC mediates the documented rise in Ca and, perhaps, other toxic effects of Pb .i
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1. Introduction
 .Lead Pb poisoning is the most common pre-
ventable disease in the pediatric age group in the
w xUnited States 1 . Based on the Centers for Disease
Control definition of Pb poisoning blood Pb)10
.mgrdl , at least one in ten preschool aged children
w xare at risk for developing Pb poisoning 2 . Blood Pb
levels as low as 10 mgrdl are associated with impair-
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w xments in mental development 3,4 , disturbances in
w xcardiovascular function 5 and decreased skeletal
w xgrowth 6,7 . Osteoblastic bone cells, the bone form-
ing cells, are a sensitive target of Pb2q toxicity. Bone
2q  2q.is the principal site of Pb and Ca deposition in
w xthe body 8 . Epidemiologic evidence has demon-
strated a negative correlation between blood Pb levels
w xand skeletal growth in children 9 .
Lead characteristically perturbs processes linked to
calcium and the calcium messenger system. Pb2q
w 2qxincreases Ca in osteoblastic bone cells andi
dampens the response of these cells to stimulation by
w xcalciotropic hormones 10,11 . We have previously
shown that Pb2q produces an increase in Ca2q influx
w 2qx w xand a rise in Ca 12 . There are several possiblei
2q w 2qxmechanisms for the Pb -induced increase in Ca ,i
the most likely is that Pb2q stimulates the opening of
a Ca2q channel via the activation of PKC. We and
others have shown that Pb2q at extremely low con-
 y9 .centrations -10 M can directly activate PKC
wfrom brain tissue and adrenal chromaffin cells 15–
x17 . In UMR-106 cells, which, like ROS 17r2.8
cells, demonstrate an osteoblastic phenotype, stimula-
w 2qxtion of PKC with phorbol esters elevates Ca i
2q w xthrough the activation of a Ca channel 18 .
 .Protein kinase C PKC is a family of
serinerthreonine kinases originally characterized by
calcium-dependent, phospholipid-dependent activa-
w xtion 13,19–21 . These kinases are considered inte-
gral to signal transduction via the calcium messenger
system. PKC phosphorylation of substrates occurs
upon translocation of the enzyme to the membrane
from the cytosol and activation by diacylglycerol
 .DAG as the result of a signal transduction cascade
w x 2q y716 . Ca activation occurs in the range from 10
to 10y5 M and is essential for PKC binding to
w xphospholipid membranes 16,17 . The PKC family
now includes more than the Ca2qrDAGrphospholi-
 .pid-dependent kinases or conventional PKCs cPKC .
These include Ca2q-independent or novel PKCs
 . 2qnPKC and Ca -independent DAG-independent
 . 2qatypical PKCs aPKC . We hypothesize that Pb
activates the cPKC isoforms by substituting for Ca2q
w x13,19–21 .
In the following study, we determine the require-
ment for PKC activation in the Pb2q-induced rise in
w 2qxCa by using the specific PKC inhibitor calphostini
C. Calphostin C specificity for PKC is based on its
interaction with the regulatory domain of PKC rather
than the catalytic domain. Calphostin C, by acting at
the C-1 region of the regulatory domain, a region not
found in kinases other than PKC, demonstrates an
apparent exclusive selectivity for inhibition of PKC
w x21–24 .
The purpose of this study was to determine whether
activation of PKC mediates Pb2q induced changes in
w 2qx  .Ca in osteoblastic bone cells ROS 17r2.8 cells .i
We defined the contribution of PKC activation in
2q w 2qxmediating the Pb induced rise in Ca by thei
following series of experiments. First, we determined
2q w 2qxthe dose dependent Pb induced rise in Ca .i
Second, we examined whether direct activation of
 .PKC with phorbol ester PMA treatment elevates
w 2qxCa . Third, we evaluated whether selective inhi-i
bition of PKC by calphostin C will prevent the Pb2q
w 2qxinduced rise in Ca . Finally, we assessed whetheri
Pb2q can directly activate PKC from these cells.
These studies were made possible by using 1,2-
 . X Xbis 2-amino-5-fluorophenoxy ethane N, N, N , N -te-
 . 19traacetic acid 5F-BAPTA and F-NMR. 5F-
BAPTA is a divalent cation chelator and indicator.
When observed by 19F-NMR, it displays distinct
resonances for free 5F-BAPTA and a number of
w xdivalent cation complexes 16,25 . 5F-BAPTA forms
high affinity complexes with essential metals, includ-
ing: Ca2q, Zn2q, Fe2q and Mn2q; and with toxic
metals, such as Pb2q, as well as Cd2q, Hg2q, and
Ni2q. The resonance intensities of free 5F-BAPTA
and each metal complex is directly proportional to its
concentration in the sample. Thus, with knowledge of
the 5F-BAPTA-metal dissociation constants, this
method enables us to identify and measure the free
ion concentrations of several metals simultaneously.
Cells are loaded with 5F-BAPTA by incubating them
with the acetoxymethyl ester of 5F-BAPTA. The
acetoxymethylester is cleaved within the cells by the
action of esterases; and the tetraacetic acid of 5F-
w xBAPTA is trapped within the cells 25 . In this way,
5F-BAPTA can be used as an intracellular indicator
w 2qxfor Ca , as well as the other divalent cations listed
above. This method has been effectively used to
simultaneously measure intracellular free concentra-
2q 2q 2q w xtions of Ca , Pb and Zn 10–12,16,25 . Fur-
thermore, 5F-BAPTA can be used as the divalent
cation buffer and indicator in the PKC reaction mix-
w x w 2qxtures 16 . This provides for the construction of Ca
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w 2qxand Pb activation curves of PKC from directly
measured metal concentrations. It also identifies and
measures concentrations of other metals which might
be present and contribute to the activation of PKC.
2. Materials and methods
2.1. Materials
The 5F-BAPTA was obtained from Molecular
 . w 32 xProbes Eugene, OR . g- P ATP was purchased
from Du Pont-New England Nuclear Wilmington,
.  .DE . D O was from Wilmad Buena, NJ . All metals2
except magnesium acetate used in the study were
 .high purity metal salts G99.999% from G.F. Smith
 .Chemicals Columbus, OH . Magnesium acetate and
all other chemicals were obtained from Sigma Col-
.umbus, OH .
2.2. Cell culture
ROS 17r2.8 cells were maintained and grown to
confluence in 75 cm2 flasks in Ham’s F-12 nutrient
mixture supplemented with 5% fetal bovine serum
 .and 28 mM Hepes buffer, pH 7.4 F-12 medium . For
PKC assays, cells were rinsed, scraped and sonicated,
as decribed below. For treatement of cells and deter-
w 2qxmination of Ca , cells were attached to microcar-i
riers, as follows. Two days before NMR observations
were made, the ROS 17r2.8 cells were harvested by
 2q 2qtrypsinization 0.01% in Ca -Mg -free Hanks’ bal-
.anced salt solution and attached to collagen-coated
 .microcarriers Cytodex 3, Pharmacia , which had been
swollen in saline and equilibrated in F-12 medium.
6.0=107 cells were seeded onto 5 ml of swollen
 .beads ;0.4 g dry wt . ROS 17r2.8 cells on micro-
carrier beads were maintained in 500 ml of F-12
medium in a one liter siliconized glass Techne stir
vessel at 35 rpm, 378C, in 95% air, 5% CO , humidi-2
fied atmosphere. Upon attachment and flattening,
complete confluence was achieved within 24 hrs. The
medium was changed twice daily.
[ 2q]2.3. Ca measurements using 5F-BAPTA andi19F-NMR
NMR measurements were conducted on ROS
17r2.8 cells attached to micro-carriers following a
40 min loading period with 20 mM of the ace-
toxymethylester of 5F-BAPTA followed by a 1 h
equilibration in fresh media. NMR measurements of
the cells were performed using a Varian 500 NMR
spectrometer equipped with a 10 mm probe tuned to
470.3 MHz for fluorine-19 and a flow-through cell
w xperfusion system 25 . NMR signals were acquired
using an acquisition time of 0.8 s, and a pulse angle
of 908. Each spectrum represents the Fourier transfor-
mation of the sum of 1000 free induction decays over
a time interval of 13 min 20 s. The identities of the
various spectral peaks for 5F-BAPTA and its metal
w xcomplexes have been previously established 16,28 .
The concentrations for free and metal bound forms of
5F-BAPTA were obtained based on the integrated
intensities of the respective resonance peaks using
 . 2qVarian software version 6.1 . Free Ca concentra-
tions were calculated from the measured resonance
intensity ratios using the following equation:
q2M y5FyBAPTAq2M sK P 1 .d 5FyBAPTA
Where M is Ca; and the K for Ca2q-5F-BAPTA isd
y7 w x5.0P10 M under the conditions of the assay 12,25 .
Cells were monitored for 40 min to determine base-
w 2qxline Ca and then treated by addition of treat-i
ments directly to the superfusion medium to achieve
sustained exposure concentrations of treated cells in
w 2qxthe flow through NMR tube apparatus. Ca wasi
w 2qxmeasured for 40–80 min of treatment. Each Ca i
measured by this method represents the average intra-
cellular concentration of this ion in a population of
cells over a time interval of 13 min 20 s. Values of
w 2qx  .Ca are given as the mean"standard error SEi
based on 3–5 separate preparations of each treatment
regimen.
2.4. PKC assay
Protein kinase C activity was determined by mea-
suring phosphatidylseriner1,2-diolein dependent in-
corporation of 32P from ATP into histone III-S and
endogenous trichloroacetic acid precipitable proteins
in the 100 000=g supernatant from homogenized
ROS 17r2.8 cells, using a previously described
w xmethods 16 . Briefly, ROS 17r2.8 cells were soni-
cated in 0.32 M sucrose, 50 mM Hepes buffer pH
.7.5 , 10 mM EDTA, 2 mM EGTA, 2 mM phenyl-
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methylsulfonyl fluoride and 50 mgrml leupeptin and
centrifuged at 100 000=g for 60 min. 12.5 ml of the
supernatant was added to a reaction mixture contain-
ing 2 mM 5F-BAPTA, 40 mM Hepes, 0.5 mM
w 32 x magnesium acetate, 100 mM g- P ATP 120
.cpmrpmol , 50 mgrml leupeptin, 0.1 mgrml his-
tone III-S with and without phospholipid 24 mg
.phosphatidylseriner1.6 mg 1,2-diolein and selected
concentrations of Ca2q or Pb2q in a final volume of
250 ml. ATP and phospholipid were added to the
reaction mixture just prior to addition of the super-
natant to start the reaction. The reaction was carried
out for 3 min at 308C. The reaction was stopped by
addition of 1 ml of ice-cold 25% trichloroacetic acid;
and the precipitate was collected over a Millipore
 .filter 0.45 mm . The reaction tubes were washed
three times with 2 ml of 5% trichloroacetic acid; and
each wash applied to the filter. The filters were then
washed two times with 5 ml of 5% trichloroacetic
acid, dissolved in scintillation fluor, and counted for
radioactivity. Protein kinase C activity was deter-
mined by subtracting 32P incorporation into histone
in the absence of added phospholipid background
. 32phosphorylation from the amount of P incorpo-
rated into histone in the presence of added phospho-
lipid. Protein was measured according to the method
w xof Schacterle and Pollock 26 . Activity is expressed
as nmol of phosphate incorporated per mg protein per
min and plotted versus free Ca2q or Pb2q concentra-
tion.
2.5. Free Ca2q and Pb2q determinations using 19F
( )nuclear magnetic resonance NMR
NMR measurements were conducted on assay mix-
tures identical to those used in the PKC assays except
w 32 xthat 100 mM ATP was added without g- P ATP
and the final mixture contained 30% D 0. NMR2
measurements of the 5F-BAPTA samples were per-
formed using a Varian 500 NMR spectrometer
equipped with a 10 mm probe tuned to 470.3 MHz
for fluorine-19. NMR signals were acquired using a
908 pulse angle, an acquisition time of 0.4 s and a 4.4
s recycle time. Each spectrum represents the Fourier
transformation of the sum of 12 free induction de-
cays. The concentration ratios of free and metal-bound
forms of 5F-BAPTA were the ratios of the integrated
intensities of their respective resonance peaks. Free
Ca2q and Pb2q were calculated from the integrated
 . 2qintensities using Eq. 1 . Where M is the metal of
concern and the K is dissociation constant for thed
M2q-5F-BAPTA complex. Free 5F-BAPTA and its
Ca2q, Pb2q and Zn2q complexes give rise to distinct
resonances which have been previously described
w x 2q12,25 . Mg demonstrates a very low affinity inter-
action with 5F-BAPTA and does not give rise to a
w xdistinct resonance signal under these conditions 25 .
K s for the M2q-5F-BAPTA complexes were cor-d
rected for the conditions of the PKC assay, 308C, pH
7.5, and an ionic strength of 0.014 M, using the
Debye-Huckel limiting law, as applied in Chelator,
w xan IBM PC program designed for this purpose 27 .
With these corrections, the K for Ca2q-5F-BAPTAd
was 5.5P10y8 M, the K for Pb2q-5F-BAPTA wasd
2.2P10y11 M, and the K for Zn2q-5F-BAPTA wasd
7.6=10y10 M for the conditions of the PKC assay
w x16 .
3. Results
2q [ 2q]3.1. PKC mediation of Pb induced rise in Ca i
w 2qxThe Ca in ROS 17r2.8 cells was measuredi
using the divalent cation indicator, 5F-BAPTA and
19F-NMR. Cells were observed by 19F-NMR and
w 2qxmonitored for 40 min to determine baseline Ca i
 .and then treated as noted Fig. 1 for 40 min in a flow
w 2qxthrough NMR tube apparatus during which Ca i
was measured. Treatment with 10 mM phorbol 12-
 .myristate 13-acetate PMA , a known, direct activator
w 2qxof PKC, produced a rise in Ca from a baseline ofi
125 nM to 200 nM. Pb2q treatment at 1 and 5 mM
w 2qxproduced elevations in Ca to 170 nM and 230i
nM, respectively. Pretreatment with calphostin C, a
potent and specific inhibitor of PKC activation, failed
w 2qxto produce a change in Ca ; and prevented anyi
w 2qx 2qsignificant rise in Ca in response to Pb treat-i
ment. These data indicate that PKC activation ele-
w 2qx 2q w 2qxvates Ca , and Pb treatment elevates Ca ,i i
while inhibition of PKC activation prevents the Pb-
w 2qxinduced rise in Ca . It follows, therefore, that thei
2q w 2qxPb -induced elevation in Ca is mediated via thei
activation of PKC. The next logical step was to
determine whether Pb2q can directly activate PKC in
ROS 17r2.8 cells.
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2q  . 2q w 2qx w 2qxFig. 1. The effect of Pb , PMA, Calphostin C CC , and Pb qCC on Ca in ROS 17r2.8 cells. Bars indicate Ca as the "SEi i
based on measurements in 3–5 separate cell preparations. )Treatment means differ from control mean, PF0.05.
3.2. Lead acti˝ation of protein kinase C
PKC activity was measured as described above.
The specific free concentrations of Ca2q and Pb2q
were set using the divalent cation chelator and indica-
tor, 5F-BAPTA. Thus, we directly confirmed the
w 2qx w 2qx 19Ca and Pb in the PKC reaction mix by F-
NMR. Free Pb2q activates PKC in the range from
y11 y7  . y1010 to 10 M Fig. 2 , with an K of 1.1=10act
 .M and maximum reaction velocity V of 1.08max
y1 y1  . 2qnmol fl mg fl min Fig. 3A , whereas Ca acti-
y8 y3  .vates PKC in the range of 10 –10 M Fig. 2 ,
with a K of 3.6=10y7 M, and a V of 1.12act max
y1 y1  .nmol fl mg fl min Fig. 3B . Each K and Vact max
was determined using linear regression of data plot-
ted on a double reciprocal plot 1rV vs. 1rmetal
.concentration . These results demonstrate the feasibil-
w 2q x w 2q xFig. 2. Free Pb and free Ca activation of PKC. Error
bars indicate SD based on assays performed in triplicate.
ity of setting specific free metal concentrations and
measuring PKC activation over a wide range of
concentrations. By using 5F-BAPTA as both chelator
and indicator, it is possible to construct PKC activa-
tion curves based on directly measured free metal
Fig. 3. Double reciprocal plots of free metal ion concentrations
 . 2qversus PKC activity. Top graph A illustrates Pb activation
 . 2qand bottom graph B shows Ca activation.
( )F.A.X. Schanne et al.rBiochimica et Biophysica Acta 1360 1997 247–254252
concentrations instead of expressing the metal con-
centration as calculated values or total added metal.
4. Discussion
These data demonstrate that treatment of osteo-
 .blastic bone cells ROS 17r2.8 with PMA, a potent
w 2qxPKC activator, induces a rise in Ca . This sug-i
gests that activation of PKC in ROS 17r2.8 cells
w 2qxcaused an increase in Ca . These data also showi
2q w 2qxthat Pb increased Ca in ROS 17r2.8 cells in ai
dose-dependent manner. Therefore, both PMA and
2q w 2qxPb caused an increase in Ca above basali
levels in ROS 17r2.8 cells. This common result did
not demonstrate directly that Pb2q acted via activa-
tion of PKC. However, calphostin C, an inhibitor of
PKC, prevented the Pb2q-induced elevation of
w 2qxCa . Taken together, these data suggest that thei
2q w 2qxeffect of Pb on Ca is mediated through thei
activation of PKC. Additional data from the analysis
of PKC activation plots support this hypothesis. Ca2q
at free concentrations of 10y8 to 10y3 M directly
activated PKC in ROS 17r2.8 cells. Pb2q at free
concentrations of 10y11 to 10y7 M also directly
activated PKC in the absence of activating concentra-
tions of Ca2q. Therefore, Pb2q activated PKC as
effectively as Ca2q but at concentrations approxi-
mately 3000 times lower then those of Ca2q. These
data demonstrate that PKC in ROS 17r2.8 cells is a
direct high affinity target of Pb2q and supports the
hypothesis that Pb2q activation of PKC is responsible
2q w 2qxfor the Pb -induced rise in Ca .i
As demonstrated here, 5F-BAPTA and 19F-NMR
provide an effective approach to measure the effects
 y7 .of very low free concentrations less than 10 M of
heavy metals on enzymes and biological processes.
The use of 5F-BAPTA as both buffer and indicator
allows the construction of PKC activation curves
from directly measured metal concentrations and pro-
vides identification and measurement of concentra-
tions of other metals which may be present and
contribute to the activation of PKC.
Mechanistically, in addition to its effects on
w 2qx 2qCa , Pb interaction with PKC may mediate ai
variety of toxic sequelae induced by fundamental
alterations in the PKC signal transduction system in
these cells. The presence of Pb2q in place of Ca2q in
the activation complex of PKC appears to alter and
limit the responsiveness of the PKC pathway to a
given stimulus. In fact, there is evidence indicating
2q that Pb does change the response of cells ROS
. 2q17r2.8 to stimuli. We have shown that Pb in-
 .hibits the parathyroid hormone PTH -induced rise in
w 2qxCa , while having no effect on PTH-inducedi
w x 2qadenylate cyclase activation 10 . Pb treatment re-
w 2qxduces the rise in Ca and inhibits production ofi
osteocalcin in ROS 17r2.8 cells in response to
 . w x 2q1,25 OH vitamin D 28 . Pb also inhibits EGF-2 3
induced collagen synthesis in osteoblastic bone cells
w x29 . Thus, PKC activation is a common signal trans-
duction pathway involved in the responses of osteo-
 .  .blastic bone cells ROS 17r2.8 to PTH, 1,25 OH 2
vitamin D and EGF. The current study demonstrates3
that PKC is a direct, high affinity target of Pb2q in
osteoblast-like cells. The direct interaction of Pb2q
with PKC in ROS 17r2.8 cells may disrupt or un-
couple the PKC mediated responses from these nor-
mal physiological stimuli. In this way, low concentra-
tions of Pb2q in bone tissue, concentrations that may
have little effect on the resting activities of bone
cells, could have important, if not severe effects, on
the response of osteoblastic bone cells to normal
hormonal regulation. Since the osteoblast is the pri-
mary cell responsible for laying down matrix and the
growth of bone, such effects could readily explain the
significant impact of low levels of Pb on the height
w xof stature in children 6,7,9 .
These data extend previous reports indicating, in
general, that Pb2q, directly or indirectly, is an activa-
w xtor of PKC. Kern and Audesirk 30 reported that the
effects of Pb2q on rat hippocampal neurons were
apparent on calmodulin-dependent protein kinases or
cAMP-dependent protein kinase, although direct
measurements of PKC activity were not reported. In
partially purified rat brain, 10y10 M Pb2q, added to
2q w xtotal Pb in the medium, activated PKC 14 . In rat
brain microvessels and in broken cell preparations,
mM concentrations of Pb2q activated PKC at levels
2q w xcomparable to Ca 31 . Furthermore, when mi-
crovessels were preincubated with mM Pb2q, PKC
activity was redistributed from the cytosolic to the
particulate fraction without further activation of the
enzyme; and the authors suggested that Pb2q mimics
2q w xor substitutes for Ca in PKC activation 31 . A
w x 2qthird report 32 showed that Pb increased mem-
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brane associated PKC in C6 astioglial and en-
thothalial cells with a maximal response in transloca-
tion over 5–16 h of exposure to 1–10 mM Pb2q.
2q  .Moreover, Pb 1.5–20 mM was shown to activate
other loci within the PKC cascade, namely, arachi-
donic acid, phospholipase A and phospholipid2
w xmetabolism 33 . Moreover, Tomsig and Suszkiw
w x 2q 2q34,35 , using Ca and Pb buffers in permeabi-
lized cells, reported that picomolar concentrations of
w 2qx  y12 y9 .Pb range: 10 –10 M activated PKC,i
whereas nM Pb2q or mM Pb2q concentrations inhib-
ited PKC. These concentrations for PKC activation
19 are consistent with those using F-NMR as reported
. 2qherein . The authors concluded that either Pb ions
act on a Ca2q receptor or at multiple and uncharacter-
ized sites that are competitive and noncompetitive
with Ca2q.
Although free metal concentrations are reported
w xherein and in two other reports 34,35 , in most
studies, metal concentration in the medium were
unknown; and this may account for the finding that
Pb2q was about six orders of magnitude more potent
as an activator of brain PKC whereas Pb2q was less
potent than Ca2q as a PKC activator in brain mi-
w xcrovessels 14,31 . Furthermore, specific PKC iso-
forms activated by Pb2q and Ca2q are unknown.
Also, it is unknown whether Pb2q fully substitutes
for Ca2q in signal transduction; and it is unknown to
what extent Pb2q may interfere with the modulation
of the PKC cascade at one or several sites. Answers
to the above questions, as well as the extent that
Pb2q uncouples PKC-mediated signalling from
physiological responses, await future research.
It is important to point out that 19F-NMR with
w x w x5F-BAPTA 10–12,15,25 , and other techniques 30
w 2qxhave the capability now to measure Ca andi
w 2qxPb that are relevant to the human toxicology ofi
Pb2q. With this methodology, it is now possible to
w 2qx w 2qxdirectly confirm the free Ca and free Pb in
the cPKC reaction mixture at concentrations of 10y11
to 10y7 M using 5F-BAPTA as both chelator and
indicator. To gain access to the extracellular fluid
 . w 2qxECF in vivo, low molecular weight Pb at con-
centrations between 10y11–10y7 M traverse plasma
w xto the ECF 39 thereby exposing bone cells to sub-
nanomolar concentrations that are resolved by 19F-
w 2qxNMR. Furthermore, it is noteworthy that Pb in
serumrplasma in normally and excessively exposed
adults, measured by IDMS, electrodes and 19F-NMR
w x y12 y736–39 , is in the range of 10 –10 . Furthermore,
w 2qx wthe concentrations of Pb reported by us 10–i
x w 2qx12,15,25 are consistent with cytosolic Pb con-i
 .centrations in the picomolar range in exposed chil-
w xdren 14,31 . Hence, our experimental design permits
w 2qxdirect Pb measurements that are relevant to the
w 2qx 2qhuman toxicology of Pb . Blood Pb values that
define childhood Pb2q poisoning are G10 mgrdl or
y6 w 2qxabout 10 M. In view of the above values of Pb
in serumrplasma, bound and free, 19F-NMR mea-
w 2qx y11 y7sures Pb precisely in the range of 10 –10
M, concentrations that are relevant to early childhood
2q w xPb poisoning 1 .
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